Evidence map›Paper›PMID 33381583›Full record

ArticleBioMed research international2020

Systemic Immune-Inflammation Index Is Superior to Neutrophil to Lymphocyte Ratio in Prognostic Assessment of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.

Cong Jiang, Yubo Lu, Shiyuan Zhang, Yuanxi Huang

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05468710 (The Prognostic and Predictive Role of Inflammatory Blood Markers in Early and Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy), which is not on this map. Cited by 34 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 8 pooled it
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05468710 unknown statusnot on this mapstarted 2022, after this paper: background citation

The Prognostic and Predictive Role of Inflammatory Blood Markers in Early and Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

TypeobservationalSponsorAin Shams UniversityRan2022 to 2023Enrolled150ConditionsBreast Cancer
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 8 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Cong JiangDepartment of Breast Surgery, Tumor Hospital Affiliated to Harbin Medical University, Harbin 150086, China.ORCID https://orcid.org/0000-0002-6436-4386
Yubo LuDepartment of Breast Surgery, Tumor Hospital Affiliated to Harbin Medical University, Harbin 150086, China.ORCID https://orcid.org/0000-0001-8920-1797
Shiyuan ZhangDepartment of Breast Surgery, Tumor Hospital Affiliated to Harbin Medical University, Harbin 150086, China.ORCID https://orcid.org/0000-0002-1123-9821
Yuanxi HuangDepartment of Breast Surgery, Tumor Hospital Affiliated to Harbin Medical University, Harbin 150086, China.ORCID https://orcid.org/0000-0002-6265-0688
Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

resultsSII, NLR, and PLR did not define patient groups with distinct clinicopathological characteristics. SII, NLR, and PLR cut-off values were 547, 2.13, and 88.23, as determined by ROC analysis; the corresponding areas under the curve (AUCs) were 0.625, 0.555, and 0.571, respectively. Cox regression models identified SII as independently associated with OS. Patients with low SII had prolonged OS (65 vs. 41 months,

conclusionOur study suggests that the pretreatment SII value is significantly correlated with OS in breast cancer patients undergoing NAC and that the prognostic utility of SII is superior to that of NLR and PLR.

Indexed as

Antineoplastic AgentsArea Under CurveBreast NeoplasmsFemaleHumansImmune SystemInflammationKaplan-Meier EstimateLymphocytesMiddle AgedNeoadjuvant TherapyNeutrophilsPrognosisProportional Hazards ModelsRegression AnalysisRetrospective StudiesAntineoplastic Agents

Identifiers

PMID33381583
PMCPMC7762645
OpenAlexW3114210567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.